Accelerate Diagnostics Inc AXDX:NASDAQ

Last Price$19.07Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 5/24/19
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$18.83 (100)
Ask (Size)$19.25 (100)
Day Low / HighN/A - N/A
Volume143.5 K
 

View Biotechnology IndustryPeer Comparison as of 05/24/2019

 

Accelerate Diagnostics Inc ( NASDAQ )

Price: $19.07
Change: +0.01 (0.05%)
Volume: 143.5 K
3:59PM ET 5/24/2019
 
 

Pacific Biosciences of California Inc ( NASDAQ )

Price: $6.80
Change: -0.11 (1.59%)
Volume: 2.4 M
4:00PM ET 5/24/2019
 
 

Editas Medicine Inc ( NASDAQ )

Price: $21.72
Change: +0.54 (2.55%)
Volume: 455.3 K
4:00PM ET 5/24/2019
 
 

Atara Biotherapeutics Inc ( NASDAQ )

Price: $23.21
Change: -0.28 (1.19%)
Volume: 378.8 K
4:00PM ET 5/24/2019
 
 

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $14.95
Change: -0.05 (0.33%)
Volume: 13.1 K
4:00PM ET 5/24/2019
 

Read more news Recent News

Accelerate Diagnostics Beats Q4 Loss Per Share Estimates and Meets on Sales
4:08PM ET 2/19/2019 MT Newswires

Accelerate Diagnostics (AXDX) said Tuesday that it recorded Q4 net loss of $22.2 million, or a $0.41 loss per share, widening from the previous year's...

Accelerate Diagnostics Issues Fiscal Q4, FY18 Revenue Guidance Below Street Estimates
2:03PM ET 1/07/2019 MT Newswires

Accelerate Diagnostics (AXDX) said Monday that total revenue for fiscal Q4 is expected to be $1.8 million, compared to $2.1 million in the same period in...

Insider Trends: Insider Purchase Continues Accelerate Diagnostics Positive Trend
2:06PM ET 11/30/2018 MT Newswires

On Nov 28, 2018, Director, Thomas D Brown, bought 10,000 shares in Accelerate Diagnostics (AXDX) for $136,454. After the Form 4 filing with the SEC, Brown...

Insider Trends: 90-Day Buying Trend Prolonged with Insider Purchase of Accelerate Diagnostics Stock
9:42PM ET 11/13/2018 MT Newswires

John Patience, 10% Owner and Director, purchased 10,000 shares in Accelerate Diagnostics (AXDX) for $149,600 on Nov 08, 2018. Patience has control over...

Company Profile

Business DescriptionAccelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ. View company web site for more details
Address3950 South Country Club Road
Tucson, Arizona 85714
Phone+1.520.365.3100
Number of Employees287
Recent SEC Filing05/24/20194
President, Chief Executive Officer & DirectorLawrence L. Mehren
Head-OperationsKurt Reinhardt
CFO, Secretary & Chief Accounting OfficerSteven Reichling
Chief Scientific OfficerRomney Humphries

Company Highlights

Price Open$19.14
Previous Close$19.06
52 Week Range$10.23 - 24.75
Market Capitalization$1.0 B
Shares Outstanding54.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/05/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.65
Beta vs. S&P 500N/A
Revenue$5.7 M
Net Profit Margin-1,348.16%
Return on Equity-130.92%

Analyst Ratings as of 05/17/2019

Buy
2
Overweight
0
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset